VanEck Pharmaceutical ETF (PPH)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
VanEck Pharmaceutical ETF (PPH) trades at $110.02. VanEck Pharmaceutical ETF (PPH) aims to mirror the performance of the MVIS US Listed Pharmaceutical 25 Index (MVPPHTR). Market cap: $649.68M, Sector: Financial services.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for PPH: PPH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PPH against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PPH: 1/1 perspectives are bearish.
How is this calculated? →VanEck Pharmaceutical ETF (PPH) Financial Services Profile
VanEck Pharmaceutical ETF (PPH) provides targeted exposure to the pharmaceutical industry by tracking the MVIS US Listed Pharmaceutical 25 Index. With a focus on companies involved in drug research, development, and sales, PPH offers investors a concentrated investment vehicle within the broader healthcare sector, exhibiting a beta of 0.54.
What Is the Investment Thesis for PPH?
VanEck Pharmaceutical ETF (PPH) offers a focused investment in the pharmaceutical sector, tracking the MVPPHTR index. With a beta of 0.54, PPH exhibits lower volatility compared to the broader market. The fund's value is driven by the performance of its constituent pharmaceutical companies, influenced by factors such as drug approvals, clinical trial outcomes, and regulatory changes. Growth catalysts include advancements in pharmaceutical research and development, increasing healthcare expenditure, and aging global population. However, potential risks involve regulatory hurdles, patent expirations, and competition from generic drugs. Investors may want to evaluate these factors when evaluating PPH's potential return.
Based on FMP financials and quantitative analysis
PPH Key Highlights
- PPH seeks to replicate the performance of the MVIS US Listed Pharmaceutical 25 Index (MVPPHTR).
- The ETF focuses on companies involved in pharmaceutical research, development, production, marketing, and sales.
- PPH has a market capitalization of $649.68M.
- The ETF exhibits a beta of 0.54, indicating lower volatility compared to the overall market.
- PPH does not offer a dividend yield.
Who Are PPH's Competitors?
PPH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BBH VanEck Biotech ETF | $210.62 | -0.34% | $365.62M | 47 |
| BKMC BNY Mellon US Mid Cap Core Equity ETF | $122.87 | +0.45% | $654.46M | 47 |
| CXSE WisdomTree China ex-State-Owned Enterprises Fund | $38.18 | +1.33% | $522.58M | 44 |
| EBI Longview Advantage ETF | $64.90 | +0.43% | $658.97M | 47 |
| FYC First Trust Small Cap Growth AlphaDEX Fund | $124.03 | +0.43% | $1.27B | 47 |
| NXDT NexPoint Diversified Real Estate Trust | $5.53 | +3.08% | $285.77M | 73 |
| GENB Generate Biomedicines, Inc. | $17.03 | -2.18% | $2.18B | 72 |
| SII Sprott Inc. | $118.11 | +2.72% | $3.05B | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PPH's Key Strengths?
- Targeted exposure to the pharmaceutical industry.
- Diversified portfolio of pharmaceutical stocks.
- Replicates a well-known index (MVPPHTR).
- Relatively low beta (0.54) compared to the broader market.
What Are PPH's Weaknesses?
- Concentrated sector exposure.
- No dividend yield.
- Subject to regulatory risks in the pharmaceutical industry.
- Dependent on the performance of a limited number of holdings.
What Could Drive PPH Stock Higher?
- Potential for new drug approvals within the portfolio holdings.
- Increasing healthcare expenditure driving demand for pharmaceuticals.
- Advancements in pharmaceutical research and development.
What Are the Key Risks for PPH?
- Regulatory changes impacting drug pricing and approval processes.
- Patent expirations leading to increased competition from generic drugs.
- Clinical trial failures affecting the value of portfolio holdings.
- Market volatility impacting the overall performance of the ETF.
What Are the Growth Opportunities for PPH?
- Advancements in Biotechnology: The biotechnology sector is experiencing rapid advancements, leading to the development of novel therapies and drugs. This growth can positively impact the performance of pharmaceutical companies held within PPH. As new drugs receive regulatory approval and gain market adoption, the ETF stands to benefit from the increased revenue and profitability of its constituent companies. The global biotechnology market is projected to reach $1.5 trillion by 2028, presenting a significant growth opportunity for PPH.
- Increasing Healthcare Expenditure: Global healthcare expenditure is on the rise, driven by factors such as aging populations and increasing prevalence of chronic diseases. This trend creates a favorable environment for pharmaceutical companies, as demand for prescription drugs and medical treatments increases. PPH is well-positioned to capitalize on this growth, as its portfolio companies are involved in the development and commercialization of pharmaceutical products. Global healthcare expenditure is expected to reach $10 trillion by 2027, representing a substantial market opportunity for PPH.
- Aging Global Population: The global population is aging, with a growing proportion of individuals aged 65 and older. This demographic shift is driving increased demand for healthcare services and pharmaceutical products, as older adults are more likely to require medical treatment for age-related conditions. PPH is poised to benefit from this trend, as its portfolio companies develop and market drugs targeting diseases prevalent in older populations. The number of people aged 65 and older is projected to reach 1 billion by 2030, creating a significant growth opportunity for PPH.
- Emerging Markets Expansion: Emerging markets are experiencing rapid economic growth and increasing access to healthcare, creating new opportunities for pharmaceutical companies. As healthcare infrastructure improves and disposable incomes rise, demand for prescription drugs and medical treatments is expected to increase in these markets. PPH can benefit from this expansion, as its portfolio companies seek to expand their presence in emerging markets and capitalize on the growing demand for pharmaceuticals. The pharmaceutical market in emerging markets is projected to reach $500 billion by 2029, presenting a substantial growth opportunity for PPH.
- Personalized Medicine: Personalized medicine, which involves tailoring medical treatment to individual patients based on their genetic makeup and other factors, is gaining traction in the healthcare industry. This approach requires the development of targeted therapies and diagnostic tools, creating new opportunities for pharmaceutical companies. PPH can benefit from this trend, as its portfolio companies invest in personalized medicine research and development. The personalized medicine market is projected to reach $3 trillion by 2030, representing a significant growth opportunity for PPH.
What Opportunities Does PPH Have?
- Growth in the pharmaceutical industry driven by aging populations.
- Advancements in biotechnology and drug development.
- Increasing healthcare expenditure in emerging markets.
- Potential for new drug approvals and market expansion.
What Threats Does PPH Face?
- Regulatory changes and pricing pressures in the pharmaceutical industry.
- Patent expirations and competition from generic drugs.
- Clinical trial failures and product recalls.
- Economic downturns and reduced healthcare spending.
What Are PPH's Competitive Advantages?
- Established index-tracking methodology.
- Diversified portfolio of pharmaceutical stocks.
- Brand recognition as a VanEck ETF.
What Does PPH Do?
VanEck Pharmaceutical ETF (PPH) is designed to replicate, before fees and expenses, the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index (MVPPHTR). This index focuses on tracking the overall performance of companies actively engaged in the pharmaceutical industry. These activities span the entire value chain, encompassing pharmaceutical research and development, as well as the production, marketing, and sales of pharmaceutical products. The ETF provides investors with a targeted investment vehicle to gain exposure to the pharmaceutical sector. By investing in PPH, investors can participate in the potential growth and innovation within the pharmaceutical industry without directly selecting individual pharmaceutical stocks. The fund's objective is to offer a convenient and diversified approach to investing in this specialized market segment. As of 2026, PPH continues to serve as a tool for investors seeking to allocate capital to the pharmaceutical industry, reflecting the performance of the MVIS US Listed Pharmaceutical 25 Index.
What Products and Services Does PPH Offer?
- Tracks the performance of the MVIS US Listed Pharmaceutical 25 Index (MVPPHTR).
- Invests in companies involved in the pharmaceutical industry.
- Focuses on pharmaceutical research and development.
- Includes companies that produce, market, and sell pharmaceuticals.
- Provides investors with exposure to the pharmaceutical sector.
- Offers a diversified approach to investing in pharmaceutical stocks.
How Does PPH Make Money?
- Replicates the MVIS US Listed Pharmaceutical 25 Index (MVPPHTR).
- Generates returns based on the performance of its constituent holdings.
- Collects management fees from investors.
What Industry Does PPH Operate In?
The asset management industry is characterized by a diverse range of investment vehicles, including ETFs like PPH that target specific sectors. The pharmaceutical industry, in which PPH invests, is driven by factors such as aging populations, increasing healthcare spending, and advancements in medical technology. Competition within the pharmaceutical industry is intense, with companies vying for market share through innovation and strategic partnerships. PPH provides investors with a way to gain exposure to this dynamic sector through a diversified portfolio of pharmaceutical stocks.
Who Are PPH's Key Customers?
- Individual investors seeking exposure to the pharmaceutical sector.
- Institutional investors looking for targeted investment vehicles.
- Financial advisors allocating client portfolios.
PPH Financials
Bull Case vs Bear Case
Bull Case
- Targeted exposure to the pharmaceutical industry.
- Diversified portfolio of pharmaceutical stocks.
- Replicates a well-known index (MVPPHTR).
- Relatively low beta (0.54) compared to the broader market.
Bear Case
- Concentrated sector exposure.
- No dividend yield.
- Subject to regulatory risks in the pharmaceutical industry.
- Dependent on the performance of a limited number of holdings.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
PPH Latest News
-
Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery
benzinga · May 20, 2026
PPH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PPH.
Price Targets
Wall Street price target analysis for PPH.
PPH MoonshotScore
What does this score mean?
The MoonshotScore rates PPH's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest VanEck Pharmaceutical ETF Analysis
Common Questions About PPH (Financial Services)
What does VanEck Pharmaceutical ETF do?
VanEck Pharmaceutical ETF (PPH) is designed to track the performance of the MVIS US Listed Pharmaceutical 25 Index (MVPPHTR). The ETF invests in a portfolio of companies involved in the pharmaceutical industry, including those engaged in research and development, production, marketing, and sales of pharmaceutical products. PPH provides investors with a targeted and diversified way to gain exposure to the pharmaceutical sector, offering a convenient alternative to investing in individual pharmaceutical stocks. The fund aims to replicate the index's performance before fees and expenses.
What are the main risks for PPH?
The main risks for VanEck Pharmaceutical ETF (PPH) are inherent to the pharmaceutical industry and the ETF structure. Regulatory risks, such as changes in drug pricing policies or approval processes, can significantly impact the profitability of pharmaceutical companies held within the ETF. Patent expirations can lead to increased competition from generic drugs, reducing revenue for branded drug manufacturers. Clinical trial failures and product recalls can negatively affect the value of individual holdings. Additionally, market volatility and economic downturns can impact the overall performance of the ETF.
How sensitive is PPH to regulatory changes in the pharmaceutical industry?
PPH's performance is significantly influenced by regulatory changes affecting the pharmaceutical industry. Changes in drug pricing policies, approval processes, and patent laws can impact the profitability and growth prospects of the companies held within the ETF. For example, government initiatives aimed at lowering drug prices could reduce revenue for pharmaceutical manufacturers, negatively affecting PPH's returns. Conversely, streamlined approval processes for new drugs could boost the value of companies with promising pipelines, benefiting PPH. Investors should closely monitor regulatory developments and their potential impact on the pharmaceutical sector.
How does PPH compare to other healthcare ETFs?
PPH differs from broader healthcare ETFs by focusing specifically on the pharmaceutical industry. While other healthcare ETFs may include companies in sectors such as biotechnology, medical devices, and healthcare services, PPH targets companies involved in the research, development, production, and marketing of pharmaceutical products. This concentrated focus can lead to higher potential returns if the pharmaceutical sector outperforms other healthcare segments. However, it also exposes investors to greater risk if the pharmaceutical industry faces challenges such as regulatory headwinds or patent expirations. Investors may want to evaluate their risk tolerance and investment objectives when choosing between PPH and other healthcare ETFs.
What are the key factors to evaluate for PPH?
Evaluate PPH on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does PPH data refresh on this page?
PPH prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven PPH's recent stock price performance?
VanEck Pharmaceutical ETF (PPH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Targeted exposure to the pharmaceutical industry. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PPH overvalued or undervalued right now?
Valuing VanEck Pharmaceutical ETF (PPH) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for PPH, limiting comprehensive insights.
- Reliance on provided data sources for factual information.